title: Acute administration of corticoids: a new and peculiar stimulus of growth hormone secretion in man.
abstract: It is widely accepted that chronic administration of corticoids in man inhibits the GH response to all of the stimuli tested so far. To study the action of corticoids administered acutely, several dexamethasone challenge tests were performed, after which GH levels were measured for 7 h. In eight volunteers, administration of 4 mg dexamethasone (Dex), iv, induced a clear-cut GH release compared with saline administration. The secretion followed an unusual pattern; basal GH levels (1.5 +/- 0.1 micrograms/L) started rising 2 h after Dex injection, reaching a peak of 17.5 +/- 4.4 micrograms/L after 3 or 3.5 h. Peak levels were maintained until 5 h post-Dex and decreased thereafter. Similar data were obtained when Dex was administered to five volunteers at the dose of 8 mg, orally, with a 30-min delay of the GH peak (19.6 +/- 7.9 micrograms/L). To study whether there was a cholinergic input responsible for the Dex action, another group of eight volunteers underwent three Dex tests (4 mg, iv) on three occasions, followed 90 min later by the administration of placebo (control), atropine (0.5 mg, iv), or pyridostigmine (120 mg, orally). The Dex-induced GH peak (20.8 +/- 5.2 micrograms/L) was not significantly increased by pyridostigmine (cholinergic agonist) treatment (24.2 +/- 4.0 micrograms/L). The blockade of muscarinic receptors by atropine induced a delay in the Dex-induced secretory peak, which appeared at 5 h. However, the Dex-atropine GH peak (14.9 +/- 4.1 micrograms/L) was not different from the Dex-placebo one. In conclusion, Dex alone is able to induce a clear-cut GH secretion in man. The stimulus followed a peculiar time pattern, with peaks levels attained 3 h after either iv or oral administration.
authors.affiliation: Department of Medicine, Hospital General Galicia, Santiago de Compostela, Spain.
authors.forename: F F
authors.initials: FF
authors.lastname: Casanueva
authors.forename: B
authors.initials: B
authors.lastname: Burguera
authors.forename: C
authors.initials: C
authors.lastname: Muruais
authors.forename: C
authors.initials: C
authors.lastname: Dieguez
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001285:Atropine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D013006:Growth Hormone / Q000097:blood* / Q000378:metabolism; D013007:Growth Hormone-Releasing Hormone / Q000037:antagonists & inhibitors / Q000502:physiology*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D011729:Pyridostigmine Bromide / Q000008:administration & dosage; D013997:Time Factors
chemical_list: D001285:Atropine; D003907:Dexamethasone; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone; D011729:Pyridostigmine Bromide